NASDAQ Seattle Genetics,Inc. false 0001060736 0001060736 2020-10-19 2020-10-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 19, 2020

 

 

Seagen Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   0-32405   91-1874389

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(I.R.S Employer

Identification No.)

21823 30th Drive SE

Bothell, Washington 98021

(Address of principal executive offices, including zip code)

(425) 527-4000

(Registrant’s telephone number, including area code)

Seattle Genetics, Inc.

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001   SGEN   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Item 7.01

Regulation FD Disclosure.

On October 19, 2020 CT, Seagen Inc. (the “Company”) filed a complaint in the U.S. District Court, the Eastern District of Texas, against Daiichi Sankyo Co., Ltd. (“DSC”) to commence an action for infringement of the Company’s U.S. Patent No. 10,808,039 by DSC’s importation into, offer for sale, sale, and use in the United States of DSC’s ENHERTU® product (DS-8201). The patent is one of many the Company holds covering its proprietary ADC technology, resulting from decades of research and development effort by the Company’s scientists and millions of dollars of investment by the Company. The complaint is available at https://www.seagen.com/news.

This action is separate from the on-going arbitration brought by the Company against DSC over ownership of certain technology used by DSC in DS-8201 and other drug candidates. In the arbitration, the Company contends that the linker and other ADC technology used in these drug candidates are improvements to the Company’s pioneering ADC technology, the ownership of which was assigned to the Company under the 2008 collaboration agreement between DSC and the Company.

The Company intends to vigorously pursue both legal actions.

The information furnished under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SEAGEN INC.
Date: October 19, 2020     By:  

/s/ Jean I. Liu

      Jean I. Liu
      Executive Vice President, Legal Affairs & General Counsel
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Seagen Charts.
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Seagen Charts.